TipRanks

TipRanks Recent News

Your Favorite Analyst's Favorite Analyst: Which Sell Side Firm Has The Most Buy Ratings From Its Peers?
What You Should Know About The Drug Approval Valeant Could Receive This Week
The Top 11 Analysts On TipRanks And What They Cover
Victor Anthony Upgrades Pandora To Buy, Take-Out Price Above $20 'Seems Reasonable'
Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness
Goldman Adds Agilent To Conviction List: 'EPS Drivers Are Underappreciated'
New Guidance Leads Avondale To Upgrade Matrix Service Co.
Apple Investors: Don't Freak Out About A Slowdown In China
S&P Analyst: Here's What Matters Most To Apple Next Week
Anheuser-Busch InBev: Future M&A Potential?
Why You Should Buy Any Weakness After Visa's Q1 Report
Stephens Calls Ligand 'Unique,' Sees $150/Share Coming By 2017
Taking The Plunge On Vera Bradley: Should You?
Top Analyst Bullish On Salesforce.com Following Record Quarter
Why Are Analysts So Bullish On This Tumbling Biotech Company?
This Video Game Company May Be Surging After Earnings, But A Top Analyst Warns Not To Buy The Hype
Bearish Apple Analyst Fired
The Top 20 Wall Street Analysts Of 2015
Goldman Sachs, Pepco, Walgreens Boots Alliance, E*TRADE Lead Wednesday's Top Ratings Changes
MannKind, Keryx Bio, Transocean Lead Monday's Early Movers
FMC President Buys $1M In Stock Day After Street Targets Cut
What BlackBerry, Micron And Darden Investors Can Expect This Week
Needham: Aerie Pharma's FDA Agreement 'Re-Establishes A Clinical Path Forward' For Rhopressa

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved